India’s Dr. Reddy’s Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Both companies agreed to collaborate on selecting new drug candidates, jointly advancing them through Phase IIa, when they can decide whether to license them out to another developer or take them on ahead as far as commercialization. The financial terms are being kept private.
“7TM has established a track record as one of the leading drug discovery companies focusing on GPCRs, and we are excited at the prospects of combining 7TM’s capabilities with Dr. Reddy’s to discover and develop innovative products,” said Rajinder Kumar, Dr. Reddy’s president.
No related Articles.